Leerink Partners Reiterates Market Perform Rating for Equillium (NASDAQ:EQ)

Posted by Renee Jackson on Mar 31st, 2025

Leerink Partners restated their market perform rating on shares of Equillium (NASDAQ:EQ – Free Report) in a research note issued to investors on Friday morning, Marketbeat reports. They currently have a $1.00 target price on the stock, down from their previous target price of $3.00.

Equillium Trading Down 16.9 %

Shares of EQ opened at $0.41 on Friday. The stock has a 50 day moving average of $0.76 and a 200 day moving average of $0.79. The company has a market capitalization of $14.36 million, a price-to-earnings ratio of -2.90 and a beta of 1.87. Equillium has a 12 month low of $0.37 and a 12 month high of $2.43.

Equillium (NASDAQ:EQ – Get Free Report) last released its earnings results on Thursday, March 27th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. Equillium had a negative net margin of 10.05% and a negative return on equity of 20.68%. The firm had revenue of $4.39 million for the quarter. As a group, equities research analysts predict that Equillium will post 0.14 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Equillium stock. DCF Advisers LLC increased its holdings in Equillium, Inc. (NASDAQ:EQ – Free Report) by 91.0% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 62,947 shares of the company’s stock after buying an additional 29,985 shares during the period. DCF Advisers LLC owned 0.18% of Equillium worth $47,000 as of its most recent SEC filing. 27.05% of the stock is owned by institutional investors and hedge funds.

Equillium Company Profile

(Get Free Report)

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.